MisophoniaEarly Phase 1NCT07271485
Propranolol for Misophonia
A Early Phase 1 study testing propranolol in people with Misophonia and Propanolol, run by Bloom Mental Health, LLC at 1 site in United States.
Trial summary
The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Misophonia, Propanolol, Misophonia Treatment
- What is being tested?
- propranolol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Dec 2025to 19 Dec 2026
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-65.
- Able to complete study visit(s) in Littleton, CO.
- Able to give informed consent.
- Participant reports clinically significant misophonia symptoms, as determined by answers on the standardized "Misophonia Trigger Screening Questions for Participants" form (described separately in the protocol). Specifically, participants must demonstrate relevant misophonia trigger responses that meet pre-specified minimum severity criteria detailed on this form.
- A-MISO-S rating scale severity criterion: Participants must score at least a moderate ("2") or higher on question 2 and question 3 of the Amsterdam Misophonia Scale (A-MISO-S) at screening, since this indicates clinically meaningful misophonia severity for study eligibility.
- Able to communicate misophonic distress in writing and reasonably participate in our outpatient clinical setting, meaning able to tolerate being in this outpatient clinical setting, follow the clinic rules for all patients and guests, and respond in an understandable fashion to questions administered to them.
- Must agree to follow study clinician advice and seek additional care outside of this clinic if advised (e.g., if advised to seek help from emergency services for a potentially serious adverse reaction).
- English fluency
Who cannot join
- Current use of scheduled propranolol for any condition.
- Any of the known contraindications for taking propranolol:
- cardiogenic shock
- sinus bradycardia (<50 bpm)
- greater than first degree heart block
- BP below 90/60
Show all 24Show fewer
- asthma / bronchial asthma that requires treatment or medication, and/or has caused clinical concerns within the last 5 years
- Other heart conditions that require ongoing medical treatment
- Participants with any of the following relative contraindications for taking propranolol:
- participants who have active anorexia, purging, or who are underweight (<18.5 BMI)
- Active drug or alcohol use within the last 48 hours prior to study participation, or active drug withdrawals
- A history of untreated diabetes or other endocrine disorders that could be harmed by exposure to propranolol
- history of cardiovascular disease or stroke, or symptomatic blood disorders such as anemia
- history of any other severe physical or neurological conditions that may affect their ability to participate in the study
- Participants with liver or kidney disease that would be affect or be affected by the study drug
- Participants may, depending on the circumstances as decided by the study clinician, be excluded for any of the following conditions that may have adverse reactions to propranolol, including: Raynaud disease or other peripheral vascular disease, Pheochromocytoma, Psoriasis, Thyroid disease (untreated, and affected by propranolol), Unexplained dizziness, Oxygen level below 91%, Respirations below 12 or above 20
- Participants taking any other medications that could interfere with the effects of propranolol, as determined by the study clinician (e.g. other beta blockers, alpha blockers,prazosin, clonidine, guanfacine, diuretics, calcium channel blockers, acute us of anti-anxiety medications; other medications that interfere with the adrenergic system; or medications that have a significant effect on propranolol's pharmacology that would normally affect dosing in clinical practice
- Allergy or sensitivity to propranolol, placebo ingredients, and/or capsule ingredients.
- Pregnant or nursing.
- Any of the following in 30 days prior to enrollment: active psychosis, suicidal/ self-harming / homicidal thoughts, bipolar mania, panic attacks, traumatic dissociation, Post-Traumatic Stress Disorder (PTSD) flashbacks, or psychiatric hospitalization.
- Participant self-reports or clinical interview identifies any misophonia-triggered reactions within the past year that posed a significant risk to health or safety, including suicidal or homicidal ideation, or uncontrolled physical behaviors (e.g., self-injury, aggression toward others, throwing objects, screaming, or fleeing uncontrollably). This criterion is assessed via direct structured questioning during participant screening interviews and review of participant self-reports on standardized screening questionnaires.
- Misophonia trigger symptoms are determined by a medical provider to be better explained by a condition other than Misophonia, such as hyperacusis or phonophobia.
- Inability to hear routine sounds and communication (ie severe hearing impairment), only if it interferes with ability to hear the misophonia triggers on the video.
- Participants who are triggered by the sound of water running or a car alarm (our control videos)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Bloom Mental Health
Littleton, Colorado, 80120
About this study
Official title: Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia
The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia.
The secondary goals of this study are:
- Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics.
- Evaluate the safety and tolerability of propranolol in individuals with misophonia.
- Conditions
- Misophonia, Propanolol, Misophonia Treatment
- Being tested
- propranolol, Placebo
- Medical subject headings
- misophonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
propranololDrug
A one-time dose of 20 mg propranolol
PlaceboDrug
A dose of placebo taken orally
| Study group | Role | What they receive |
|---|---|---|
| Propranolol Pill | Experimental | 10 participants will take one-time dose of 20 mg propranolol pill Receives: Drug: propranolol |
| Placebo Pill | Placebo comparator | 10 participants will take be given a matching one-time dose of placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart Rate
Heart rate was chosen as a primary biometric outcome because it reliably indicates sympathetic nervous system activation commonly observed in acute misophonia reactions. Given propranolol's established pharmacologic effect as a beta-blocker, the hypothesis is that propranolol will significantly blunt the heart rate increase typically elicited by misophonia triggers compared to placebo.
Measured: Heart rate is continuously monitored via pulse oximetry during each video presentation. The continuous measurement will start at pre-intervention and end after the intervention.
Visual Analog Scale (VAS)
The Visual Analog Scale (VAS) assesses three core emotional domains (anger, anxiety, disgust) and multiple physical sensations frequently reported during acute misophonia episodes, such as feeling hot/sweaty, heart pounding, muscle tension, trembling/shaking, and shortness of breath. Each response is rated on a sliding scale accompanied by emojis or graphics that visually represent increasing intensity of the sensations or emotions. This format leverages established evidence from acute pain and emotional-response research, demonstrating that visual analogue scales effectively capture immediate subjective states. The VAS is based on a Likert scales ranging from 0-7, 0-5, and 0-8 in some questions. Higher scores indicates more distress and a worst outcome.
Measured: The scale will be taken immediately after each video clip intervention. It will measure the participant's reaction to each clip.
Secondary outcomes (1)
Grip Strength
An innovative exploratory measure of emotional and physical intensity will also be collected using a Grip Strength Meter. This measure is specifically designed for this study to provide participants with a physical, embodied way to express their subjective feelings of anger, distress, or tension following trigger exposure.
Measured: Grip Strength measurement is subsequently performed immediately after each video exposure. This will be taken immediately after each video clip intervention in order to measure the participant's reaction to each clip.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2025
- Study start19 Dec 2025 (estimated)
- Primary completion19 Dec 2026 (estimated)
- Study completion19 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MisophoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bloom Mental Health, LLC
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jadon Webb, Bloom Mental Health, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07271485
- Sponsor's protocol ID
- 824
- Status last verified
- Nov 2025
- First submitted
- 20 Nov 2025
- Last updated
- 9 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia
- ClinicalTrials.gov ID
- NCT07271485
- Acronym / sponsor ID
- 824
- Conditions
- Misophonia, Propanolol, Misophonia Treatment
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Bloom Mental Health, LLCUniversity, hospital or other
- Study start
- 19 Dec 2025 (estimated)
- Primary completion
- 19 Dec 2026 (estimated)
- Study completion
- 19 Dec 2026 (estimated)
- First posted
- 9 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia.
The secondary goals of this study are:
- Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics.
- Evaluate the safety and tolerability of propranolol in individuals with misophonia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Propranolol Pill | Experimental | Drug: propranolol10 participants will take one-time dose of 20 mg propranolol pill |
| Placebo Pill | Placebo comparator | Drug: Placebo10 participants will take be given a matching one-time dose of placebo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age 18-65.
- Able to complete study visit(s) in Littleton, CO.
- Able to give informed consent.
- Participant reports clinically significant misophonia symptoms, as determined by answers on the standardized "Misophonia Trigger Screening Questions for Participants" form (described separately in the protocol). Specifically, participants must demonstrate relevant misophonia trigger responses that meet pre-specified minimum severity criteria detailed on this form.
- A-MISO-S rating scale severity criterion: Participants must score at least a moderate ("2") or higher on question 2 and question 3 of the Amsterdam Misophonia Scale (A-MISO-S) at screening, since this indicates clinically meaningful misophonia severity for study eligibility.
Key exclusion criteria (24 listed)
- Current use of scheduled propranolol for any condition.
- Any of the known contraindications for taking propranolol:
- cardiogenic shock
- sinus bradycardia (<50 bpm)
- greater than first degree heart block
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| propranololA one-time dose of 20 mg propranolol | Drug | Propranolol Pill |
| PlaceboA dose of placebo taken orally | Drug | Placebo Pill |
Primary outcome
Heart Rate
Time frame: Heart rate is continuously monitored via pulse oximetry during each video presentation. The continuous measurement will start at pre-intervention and end after the intervention.
Heart rate was chosen as a primary biometric outcome because it reliably indicates sympathetic nervous system activation commonly observed in acute misophonia reactions. Given propranolol's established pharmacologic effect as a beta-blocker, the hypothesis is that propranolol will significantly blunt the heart rate increase typically elicited by misophonia triggers compared to placebo.
Visual Analog Scale (VAS)
Time frame: The scale will be taken immediately after each video clip intervention. It will measure the participant's reaction to each clip.
The Visual Analog Scale (VAS) assesses three core emotional domains (anger, anxiety, disgust) and multiple physical sensations frequently reported during acute misophonia episodes, such as feeling hot/sweaty, heart pounding, muscle tension, trembling/shaking, and shortness of breath. Each response is rated on a sliding scale accompanied by emojis or graphics that visually represent increasing intensity of the sensations or emotions. This format leverages established evidence from acute pain and emotional-response research, demonstrating that visual analogue scales effectively capture immediate subjective states. The VAS is based on a Likert scales ranging from 0-7, 0-5, and 0-8 in some questions. Higher scores indicates more distress and a worst outcome.
1 secondary outcome
Grip Strength
Time frame: Grip Strength measurement is subsequently performed immediately after each video exposure. This will be taken immediately after each video clip intervention in order to measure the participant's reaction to each clip.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Misophonia
Recruiting
Transcranial Magnetic Stimulation in Misophonia
Misophonia
Not yet recruitingObservational study
Pain, Central Sensitization, and Misophonia in Lipedema
Lipedema
Not yet recruiting
Effectiveness of a Mindfulness-Based Cognitive Behavioral Mobile Intervention for Misophonia
Misophonia, Misophonia Treatment
RecruitingObservational study
Prevalence of Misophonia in Turkish High School Students
Misophonia
Recruiting
Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia
Tinnitus, Misophonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing propranolol in people with Misophonia and Propanolol, run by Bloom Mental Health, LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bloom Mental Health Clinic (303-801-1776, office@bloommh.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart Rate (time frame: Heart rate is continuously monitored via pulse oximetry during each video presentation. The continuous measurement will start at pre-intervention and end after the intervention.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.